CovidV2, Main, Exploration, bibRecord, 001380

Progress Toward In Vivo Use of siRNAs-II

Identifieur interne : 001380 ( Main/Exploration ); précédent : 001379; suivant : 001381

Progress Toward In Vivo Use of siRNAs-II

Auteurs : Garrett R. Rettig [États-Unis] ; Mark A. Behlke [États-Unis]

Source :

Molecular Therapy [ 1525-0016 ] ; 2011.

RBID : PMC:3293614

Abstract

RNA interference (RNAi) has been extensively employed for in vivo research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of in vivo RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact in vivo use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293614

DOI: 10.1038/mt.2011.263
PubMed: 22186795
PubMed Central: 3293614

Affiliations:

États-Unis

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Progress Toward <italic>In Vivo</italic>
 Use of siRNAs-II</title>
<author><name sortKey="Rettig, Garrett R" sort="Rettig, Garrett R" uniqKey="Rettig G" first="Garrett R" last="Rettig">Garrett R. Rettig</name>
<affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Integrated DNA Technologies, Inc.</institution>
, Coralville, Iowa,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Behlke, Mark A" sort="Behlke, Mark A" uniqKey="Behlke M" first="Mark A" last="Behlke">Mark A. Behlke</name>
<affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Integrated DNA Technologies, Inc.</institution>
, Coralville, Iowa,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">22186795</idno>
<idno type="pmc">3293614</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293614</idno>
<idno type="RBID">PMC:3293614</idno>
<idno type="doi">10.1038/mt.2011.263</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">000007</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000007</idno>
<idno type="wicri:Area/Pmc/Curation">000007</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000007</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000787</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000787</idno>
<idno type="wicri:Area/Ncbi/Merge">000296</idno>
<idno type="wicri:Area/Ncbi/Curation">000296</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000296</idno>
<idno type="wicri:Area/Main/Merge">001382</idno>
<idno type="wicri:Area/Main/Curation">001380</idno>
<idno type="wicri:Area/Main/Exploration">001380</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Progress Toward <italic>In Vivo</italic>
 Use of siRNAs-II</title>
<author><name sortKey="Rettig, Garrett R" sort="Rettig, Garrett R" uniqKey="Rettig G" first="Garrett R" last="Rettig">Garrett R. Rettig</name>
<affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Integrated DNA Technologies, Inc.</institution>
, Coralville, Iowa,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Behlke, Mark A" sort="Behlke, Mark A" uniqKey="Behlke M" first="Mark A" last="Behlke">Mark A. Behlke</name>
<affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Integrated DNA Technologies, Inc.</institution>
, Coralville, Iowa,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Molecular Therapy</title>
<idno type="ISSN">1525-0016</idno>
<idno type="eISSN">1525-0024</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>RNA interference (RNAi) has been extensively employed for <italic>in vivo</italic>
 research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of <italic>in vivo</italic>
 RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact <italic>in vivo</italic>
 use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Rettig, Garrett R" sort="Rettig, Garrett R" uniqKey="Rettig G" first="Garrett R" last="Rettig">Garrett R. Rettig</name>
</noRegion>
<name sortKey="Behlke, Mark A" sort="Behlke, Mark A" uniqKey="Behlke M" first="Mark A" last="Behlke">Mark A. Behlke</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001380 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001380 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3293614
   |texte=   Progress Toward In Vivo Use of siRNAs-II
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22186795" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidV2

This area was generated with Dilib version V0.6.33.
Data generation: Sat Mar 28 17:51:24 2020. Site generation: Sun Jan 31 15:35:48 2021

Serveur d'exploration Covid (26 mars)

Progress Toward In Vivo Use of siRNAs-II

Progress Toward In Vivo Use of siRNAs-II

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Covid (26 mars)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.